Docoh
Loading...

TFX Teleflex

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

Company profile

Ticker
TFX
Exchange
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
231147939

TFX stock data

(
)

Calendar

29 Jul 21
30 Jul 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Teleflex earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 361.78M 361.78M 361.78M 361.78M 361.78M 361.78M
Cash burn (monthly) (positive/no burn) 15.98M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 18.01M n/a n/a n/a n/a
Cash remaining n/a 343.77M n/a n/a n/a n/a
Runway (months of cash) n/a 21.5 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
12 Jul 21 Klasko Stephen K. M.D. Common Stock Sell Dispose S No Yes 423.95 150 63.59K 1,424.18
12 Jul 21 Klasko Stephen K. M.D. Common Stock Sell Dispose S No Yes 423.39 1,200 508.07K 1,574.18
12 Jul 21 Klasko Stephen K. M.D. Common Stock Sell Dispose S No Yes 422 2,214 934.31K 2,774.18
12 Jul 21 Klasko Stephen K. M.D. Common Stock Option exercise Aquire M No Yes 59.75 3,564 212.95K 4,988.18
12 Jul 21 Klasko Stephen K. M.D. Stock Option / Common Stock Option exercise Dispose M No Yes 59.75 3,564 212.95K 0
10 Jun 21 Cameron P Hicks Common Stock Sell Dispose S No Yes 397.21 600 238.33K 8,603.765
10 Jun 21 Cameron P Hicks Common Stock Sell Dispose S No Yes 396.3 1,205 477.54K 9,203.765
10 Jun 21 Cameron P Hicks Common Stock Sell Dispose S No Yes 395.05 1,671 660.13K 10,408.765
10 Jun 21 Cameron P Hicks Common Stock Option exercise Aquire M No Yes 121 1,800 217.8K 12,079.765
10 Jun 21 Cameron P Hicks Common Stock Option exercise Aquire M No Yes 101.12 1,676 169.48K 10,279.765

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

90.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 551 541 +1.8%
Opened positions 65 79 -17.7%
Closed positions 55 61 -9.8%
Increased positions 192 195 -1.5%
Reduced positions 182 175 +4.0%
13F shares
Current Prev Q Change
Total value 17.47B 17.46B +0.0%
Total shares 42.07M 42.44M -0.9%
Total puts 49.7K 42.9K +15.9%
Total calls 187K 195.8K -4.5%
Total put/call ratio 0.3 0.2 +21.3%
Largest owners
Shares Value Change
BLK Blackrock 5.04M $2.1B +1.4%
Vanguard 4.99M $2.07B +0.2%
TROW T. Rowe Price 4.97M $2.06B +0.6%
Wellington Management 3.02M $1.26B +11.3%
STT State Street 1.83M $761.38M -2.8%
American Century Companies 1.53M $634.14M +0.5%
JHG Janus Henderson 997.22K $414.31M +9.8%
IVZ Invesco 856.57K $355.87M -8.2%
Geode Capital Management 767.76K $318.1M +2.6%
Marshall Wace 765.93K $318.21M -13.3%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -437.12K EXIT
Wellington Management 3.02M +305.99K +11.3%
Marshall Wace North America 342.67K -226.87K -39.8%
Citadel Advisors 103.44K -169.15K -62.1%
Eagle Asset Management 119.76K +119.76K NEW
Marshall Wace 765.93K -116.99K -13.3%
MS Morgan Stanley 234.9K +99.54K +73.5%
William Blair Investment Management 404.44K -89.19K -18.1%
JHG Janus Henderson 997.22K +89K +9.8%
Montag & Caldwell 32.76K -78.43K -70.5%

Financial report summary

?
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.
  • We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: abandon, accommodate, advocate, ambulatory, ancillary, asserted, broad, calendar, center, chance, CMS, comment, decision, dismissed, Fee, hospital, immunization, lawsuit, Medline, outpatient, PFS, phase, physician, prejudice, proposed, published, quality, reached, reimbursement, reiterate, repaid, replicating, Schedule, support, type, urolift, vaccine, volume
Removed: adjustment, borrow, carried, concentrated, discretionary, disqualified, entertainment, governmental, impacting, issue, mitigation, North, pay, perspective, preferred, protect, recognizing, restricted, spread, stock, trend, vascular